Fulgent Genetics (NASDAQ:FLGT) Insider Sells $18,695.49 in Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT) insider Hanlin Gao sold 939 shares of Fulgent Genetics stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $19.91, for a total value of $18,695.49. Following the transaction, the insider directly owned 987,790 shares of the company’s stock, valued at $19,666,898.90. This trade represents a 0.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Hanlin Gao also recently made the following trade(s):

• On Tuesday, June 2nd, Hanlin Gao sold 1,688 shares of Fulgent Genetics stock. The stock was sold at an average price of $17.89, for a total transaction of $30,198.32.

Fulgent Genetics Stock Performance

Shares of NASDAQ FLGT opened at $19.61 on Monday. The company’s 50-day moving average price is $19.63 and its 200 day moving average price is $18.11. Fulgent Genetics, Inc. has a 52 week low of $13.46 and a 52 week high of $31.04. The stock has a market cap of $539.47 million, a price-to-earnings ratio of -6.95 and a beta of 0.91.

Fulgent Genetics (NASDAQ:FLGT) last announced its earnings results on Thursday, July 30th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.12). Fulgent Genetics had a negative return on equity of 4.93% and a negative net margin of 26.05%.The business had revenue of $85.39 million for the quarter, compared to analyst estimates of $94.00 million. Fulgent Genetics has set its FY 2026 guidance at -2.350–2.220 EPS. As a group, research analysts expect that Fulgent Genetics, Inc. will post -3.48 earnings per share for the current year.

Hedge Funds Weigh In On Fulgent Genetics

Several institutional investors and hedge funds have recently modified their holdings of the company. Amundi boosted its position in Fulgent Genetics by 289.2% during the first quarter. Amundi now owns 34,316 shares of the company’s stock worth $583,000 after acquiring an additional 25,500 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Fulgent Genetics by 28.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 202,820 shares of the company’s stock valued at $3,428,000 after acquiring an additional 45,279 shares during the last quarter. Legal & General Group Plc raised its holdings in Fulgent Genetics by 14.1% in the 2nd quarter. Legal & General Group Plc now owns 21,025 shares of the company’s stock valued at $418,000 after acquiring an additional 2,599 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Fulgent Genetics by 2.4% during the 2nd quarter. Rhumbline Advisers now owns 33,139 shares of the company’s stock worth $659,000 after purchasing an additional 785 shares during the period. Finally, American Century Companies Inc. lifted its stake in shares of Fulgent Genetics by 8.0% during the 2nd quarter. American Century Companies Inc. now owns 52,168 shares of the company’s stock worth $1,037,000 after purchasing an additional 3,860 shares during the period. Hedge funds and other institutional investors own 48.06% of the company’s stock.

Analyst Ratings Changes

FLGT has been the topic of a number of recent research reports. Piper Sandler upped their target price on Fulgent Genetics from $15.00 to $19.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. Weiss Ratings raised Fulgent Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. Finally, Wall Street Zen upgraded Fulgent Genetics from a “strong sell” rating to a “sell” rating in a research report on Saturday. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $27.50.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.